28.7 C
Vientiane
Monday, June 30, 2025
spot_img
Home Blog Page 1084

CDNetworks to Showcase Innovative Gaming Solutions at ICE 2025

SINGAPORE and BARCELONA, Spain, Jan. 16, 2025 /PRNewswire/ — CDNetworks, the APAC-leading network to deliver edge as a service, will present its latest gaming solutions at ICE 2025 in Barcelona, Spain on 20th – 22nd January. At the event, the company will demonstrate how its advanced solution enables game providers to deliver seamless, secure, and high-performance gaming experiences on a global scale.


The gaming industry has become one of the world’s most dynamic and fast-growing sectors. As the industry grows, cyberattacks have become more frequent, intense, and sophisticated than ever before. To tackle these evolving threats, CDNetworks is at the forefront, offering a comprehensive range of solutions that ensure both security and speed.

“Gaming is no longer just about entertainment—it’s a global ecosystem where performance and security must coexist in real-time,” said Antony Li, APAC Head of Sales at CDNetworks. “As game developers push the boundaries of speed, they’re also facing an onslaught of ever-more sophisticated cyber threats. We understand that balancing both is the key to long-term success. At ICE 2025, we’re excited to showcase how our solutions can empower game providers to stay ahead of both the game and the threat.”

Highlights of CDNetworks’ Gaming Solutions:

  • Gaming Shield (Advanced Anti-hijacking): Utilizes IP scheduling, link encryption, and hijacking monitoring to tackle network hijacking and safeguard your business comprehensively.
  • AI-Powered DDoS Protection: Provides real-time, AI-driven DDoS mitigation with 40+ scrubbing centers and 20Tbps capacity for fast and reliable defense.
  • Ultra-low Latency Streaming: Empowers a wide range of streaming use cases, including real-time game streaming, cloud gaming, and esports events, offering latencies as low as 500ms.
  • Extensive Global Network: A robust infrastructure with over 2,800 PoPs across more than 70 countries and regions.

Visit CDNetworks at Stand #5B11

Don’t miss the chance to meet CDNetworks at Stand #5B11, Hall 5. Schedule a personalized meeting to connect with their experts and experience firsthand how their innovative gaming solutions are shaping the future of the gaming industry.

About CDNetworks

With over 2,800 global PoPs, CDNetworks delivers the fastest and most secure digital experiences to end users. Our diverse products and services include web performance, media delivery, cloud security, and colocation services — all designed to spur business innovation. Visit cdnetworks.com and follow us on LinkedIn.

Daon Expands Presence in Japan as part of ELEMENTS’ acquisition of Polarify

ELEMENTS Inc., Japan, and Daon Inc. announce a long-term agreement to collaborate on identity assurance solutions

TOKYO, Jan. 16, 2025 /PRNewswire/ — Daon®, the Digital Identity Trust company, has announced a strategic partnership with ELEMENTS, Inc., Japan’s market leader in image recognition services and a parent company of Liquid,Inc., to deliver advanced identity assurance technology in Japan.

ELEMENTS has acquired the majority ownership in Polarify, a Joint Venture between SMFG, Daon and NTT Data that provides eKYC and Authentication services in Japan.  Through this acquisition, ELEMENTS will reach over 550 organizations with identity authentications exceeding 120 million transactions and will secure the No.1 market share of identity authentication solutions in Japan.

As part of this, ELEMENTS has formed a strategic partnership with Daon, a global leader in identity assurance technology, building on Daon’s role as Polarify’s core identity technology provider. This collaboration ensures a seamless transition for existing Polarify customers and creates new opportunities in identity authentication and fraud prevention. Together, ELEMENTS and Daon are poised to provide businesses with advanced tools to address evolving identity security challenges and enhance customer identity experiences.

As part of the collaboration, Liquid, Inc., a wholly owned subsidiary of ELEMENTS specializing in online identity verification services, plans to work closely with Daon to develop and promote authentication services in Japan. In addition, the partnership includes the facility to leverage the Daon TrustX identity orchestration and workflow SAAS platform to assist ELEMENTS and Liquid expand its business.

“Our partnership with ELEMENTS allows Daon to expand the reach of our technology into one of the world’s most dynamic markets,” said Tom Grissen, CEO of Daon. “ELEMENTS and Daon can transform how businesses in Japan approach customer authentication, providing them the opportunity to stay ahead of emerging threats and set the stage for further innovation in identity technology.”

“Merging ELEMENTS’ deep expertise in image recognition technology with Daon’s proven identity assurance solutions will unlock new opportunities in identity authentication and fraud prevention,” said Hiroki Hasegawa, CEO of ELEMENTS. “Working with Daon, we are well-positioned to equip businesses in Japan and overseas with the advanced tools needed to navigate evolving identity security challenges. ”

For more information about Daon’s identity solutions and this partnership, visit daon.com.

About Daon
Daon, the Digital Identity Trust company, enables market-leading organizations worldwide to easily and accurately proof, verify, authenticate, and secure customer identities at every trust point across the entire customer lifecycle. With industry-leading identity verification and biometric authentication technologies at its core, Daon’s technology ensures that customer identities are accurately verified, safely secured, and easily recovered. By mitigating fraud, reducing friction, and ensuring regulatory compliance, Daon helps businesses deliver a seamless customer experience, increase customer satisfaction, and reduce costs. Daon delivers these solutions through its AI and ML-powered platforms, available for on-premises or SaaS deployment. Leading companies in financial services, telco, travel & hospitality, and other industries choose Daon to secure and process hundreds of millions of digital identity transactions daily. Learn more at www.daon.com.

About ELEMENTS and Liquid

ELEMENTS was established in 2013 and aims to solve social issues through technologies such as biometric authentication, image recognition, and generative AI. The company’s main business at present is “LIQUID eKYC” a service provided by Liquid from 2019 that allows customers to complete identity verification required for account registration and account opening online. It offers a system that takes a photo of the user’s ID document, such as a driver’s license or My number card, or reads the IC chip, and then compares it with the user’s selfie photo, as well as a system that uses the public certification for Individuals (JPKI / smartphone JPKI).
For more information, visit: https://elementsinc.jp/global/  https://liquidinc.asia/global/

(Taiwan) CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology

TAICHUNG, Jan. 16, 2025 /PRNewswire/ — On November 2, 2024, China Medical University (CMU) and Healthcare System hosted the International Forum of Extracellular Vesicles Technology and Novel Therapeutics to highlight Taiwan’s advancements and explore new horizons in biomedical applications. Professor Randy Schekman, the 2013 Nobel prize laureate in Physiology/Medicine, was invited as keynote speaker to share his insights in Extracellular Vesicles (EV) technology. Notable scholars and industrial leaders, such as Professor Andreas Möller, Professor Houjian Cai, Professor Le Thi Nguyet Minh, Professor Johannes Grillari, and members of the International Society for Extracellular Vesicles, the Asia Pacific Societies for Extracellular Vesicles, and the Taiwan Society for Extracellular Vesicles attended the forum to discuss the latest advancements in EV research, technology, and applications.

CEO Jeng (leftmost), President Hung (second from the left), Professor Schekman (second from the right) and Superintendent Cho (rightmost) attended the forum to discuss the potential of exosomal technology in clinical applications.
CEO Jeng (leftmost), President Hung (second from the left), Professor Schekman (second from the right) and Superintendent Cho (rightmost) attended the forum to discuss the potential of exosomal technology in clinical applications.

Dr. Chang-Hai Tsai, Chairman of CMU Healthcare System, stated that this forum marks a major breakthrough in exosomal technology in precision medicine and regenerative medicine. CMU Healthcare System aims to continue the endeavor of promoting the international presence of Taiwan-based biotech industries, and to deliver better personalized healthcare to the global community. EVs are known to play a key role in aging, inflammation, disease progression and inter-cellular communication. EVs or exosomes technology will become a landmark in biological preparation development and human health.

Professor Randy Schekman provided an in-depth view of the key bridging role of exosomes in inter-cellular communication, and the latest research on quantitative science-based methods for increasing the “cargo loading” efficiency of exosomes. In his keynote speech, Professor Schekman highlighted the potential of exosome technology in achieving therapeutic goals. The keynote was moderated by Dr. Mien-Chie Hung, President of CMU.

Dr. Long-Bin Jeng, CEO of CMU Development Committee, stated that CMU Healthcare System acquired notable results in exosome studies and development. Shine-On BioMedical Co. introduced the application of HLA-G targeted exosome in cancer treatment, and demonstrated innovative technology and current development progress: using targeted exosomes loaded with chemotherapy agent for effective inhibition of breast cancer cells while reducing side effects. Shine-On BioMedical is also working on Temodal, a chemotherapy agent indicated for brain cancer, to develop a nucleic acid pharmaceutical agent aimed at reducing resistance development. By carrying such agents through the blood brain barrier using HLA-G targeted exosomes, outstanding efficacy of difficult-to-treat brain tumors such as glioblastoma multiforme (GBM) can be achieved. This will provide significant benefits to cancer patients.

CMUH’s Translational Medicine Research Center showcased dual-gene-engineered exosomes for improving neurological recovery after stroke. Partnering with Shine-Out BioTechnology Co., CMUH developed targeted exosome platforms for treating neurodegenerative diseases like Parkinson’s and Alzheimer’s. These platforms are designed to boost cellular repair and regeneration. Additionally, CMUH’s Translational Cell Therapy Center advanced CD3ε nanobody-modified exosomes, which may generate dual-targeting CAR-T cells, highlighting the forum’s commitment to clinical innovation.

Dr. Der-Yang Cho, Superintendent of CMUH, emphasized the potential of exosomal platforms in cancer and neurodegenerative treatments, aiming to reduce dosages and side effects. Despite challenges in scaling production, CMUH is dedicated to advancing clinical research and fostering international collaborations to bring cutting-edge medical technologies to patients.

CONTACT: Carolyn Chen, 100709@tool.caaumed.org.tw

Galaxy Macau Shines Brightly this Lunar New Year Unlocking a ‘Golden’ Year of Prosperity and Good Fortune


MACAU SAR – Media OutReach Newswire – 16 January 2025 – With the Lunar New Year just around the corner, Galaxy Macau™ has officially launched its Lunar New Year campaign to celebrate the most joyful and lucky time of the year. Galaxy Macau™, Broadway Macau™, and StarWorld Hotel have adorned themselves with festive decorations, showcasing the unique charm of Lunar New Year in Macau, a UNESCO World Heritage city.

Guests are invited on a journey through the “Ruyi Gate” at the Diamond Lobby to experience a series of interactive digital features, including a lucky draw to win amazing prizes.
Guests are invited on a journey through the “Ruyi Gate” at the Diamond Lobby to experience a series of interactive digital features, including a lucky draw to win amazing prizes.

From now until February 16, with thoughtfully curated experiences, including an exciting series of auspicious events, luxurious shopping offerings, and enticing rewards totalling up to MOP 8.88 million, guests can gather blessings for the year ahead and embrace a brand-new chapter of fortune and prosperity.

Immersive Digital Experience for Lunar New Year Installations

As the Chinese Spring Festival has recently been recognised as a UNESCO Intangible Cultural Heritage, Galaxy Macau, Broadway Macau, and StarWorld Hotel have been adorned with decorations inspired by the “Ruyi” knot, a piece of traditional Chinese craftsmanship symbolising good fortune and blessings, while every corner has been thoughtfully decorated to bring wishes of happiness and prosperity. This year’s decorations combine digital technology with traditional Chinese architectural elements, infusing the interiors with auspicious symbols and innovative concepts.

The God of Fortune, accompanied by Golden Boy and Jade Girl, will be visiting Galaxy Macau and StarWorld Hotel on the first five days of the Lunar New Year to bestow blessings, fortune and good luck upon everyone!
The God of Fortune, accompanied by Golden Boy and Jade Girl, will be visiting Galaxy Macau and StarWorld Hotel on the first five days of the Lunar New Year to bestow blessings, fortune and good luck upon everyone!

Beginning at the Diamond Lobby, where a giant shimmering Ruyi knot installation awaits, guests are invited on an unforgettable journey including a lucky draw in the form of innovative digital fortune sticks. Grand prizes include white gold diamond jewellery sponsored by Chow Tai Fook, shopping rewards, discounts for the “Love Between Fairy and Devil” VR Immersive Experience, and a wide selection of dining vouchers, with prizes valued at a total of MOP 8.88 million. During the festive period, guests participating in the “Galaxy Ultimate Club” photo game can also receive exclusive limited-edition Ruyi knot keepsakes, symbolising blessings for the new year.

Inspired by traditional Chinese Si He Yuan architecture, one of this year’s highlights is the “Auspicious Si He Yuan Digital House” at the Pearl Lobby. Its exterior showcases intricate Ruyi knot designs, while its interior offers an immersive digital experience. The Jade Lobby features the “Fourtune Pavilion”, where guests can enjoy an interactive calligraphy experience using digital technology to create spring couplets in their choice of Chinese character for “Good Fortune” (“Fu”). At the “Garden of Blessings” at Promenade Central, a digital garden blooms with vibrant cherry blossoms underneath giant Ruyi knots dangling from above. Every corner of the resort is imbued with festive blessings for wealth and prosperity.

Galaxy Macau’s ‘Golden Fortune Rains’ mini-game is now live. Head over to the ‘Galaxy Macau Integrated Resorts’ WeChat Mini Program to access the event page before February 16. Galaxy Macau presents a multitude of exceptional rewards. Become a Galaxy Ultimate member to participate in the mini-game to secure exclusive concert tickets, luxurious hotel stays at the Andaz Macau, dining and shopping vouchers, and unique WeChat red packet covers. These thoughtfully curated New Year gifts symbolize our sincere wishes for fortune and success in the coming year.

Exclusive New Year Collections from Luxury Brands

The Lunar New Year is the perfect time to refresh your style and pamper yourself. Galaxy Promenade offers a curated selection of world-renowned luxury brands, making it the ultimate destination for the latest fashion collections. This year, top luxury brands have launched limited-edition items exclusive to Lunar New Year along with their early Spring 2025 collections, blending festive flair with contemporary trends. From January 24 to February 9, guests can even enjoy up to 7% cashback on their shopping.

From January 15 to February 7, the DFS New Year Pop-Up store at the Pearl Lobby features exclusive Lunar New Year gift sets and limited-edition offers from popular beauty brands. Shoppers can enjoy makeup demonstrations every Friday to Sunday and earn beauty vouchers worth up to MOP 860.

Special Festive Performances with a Strong Sense of Ceremony

From January 15 to February 16, the resort will present special editions of the Galaxy Macau Diamond Show and the Crystal Lobby Show. A dazzling three-meter-tall diamond will descend gracefully amid a water display, synchronised with stunning lights and awe-inspiring music. The shimmering Crystal Lotus, constructed of 380,000 precision-cut fine crystals and 146,000 individually programmed points of light, combines cutting-edge technology with luxury, creating an immersive technicolor spectacle with traditional red and gold elements.

The resort will present special editions of the Galaxy Macau Diamond Show.
The resort will present special editions of the Galaxy Macau Diamond Show.

From the first to the fifth day of the Lunar New Year, the God of Fortune, accompanied by the “Golden Boy” and “Jade Girl”, will make appearances at Galaxy Macau and StarWorld Hotel, giving out blessings and good fortune for the year ahead. Professional lion dance troupe will also perform from the third to the fifth day, showcasing breathtaking artistry and spreading joy and blessings.

A Spectacular Performances to Expand Artistic Horizons

The Galaxy International Convention Center and Galaxy Arena, Asia’s newest premier event venues, are set to host an array of captivating performances, including “Galaxy Music Gala: Lang Lang and Macao Orchestra”, “The TF Family 2025 New Year Concert – Passion is coming!”, “Jeff Chang Ultimate Continuum World Tour Concert in Macau, Chinese New Year Special”, and “TAEYANG 2025 TOUR [THE LIGHT YEAR] IN MACAU”. Adding to the excitement, an internationally renowned music maestro will make a surprise appearance on January 19 from 12.30-1.30pm at the Pearl Lobby, performing timeless masterpieces alongside talented young artists as part of the Music Chamber Series: Young Award-Winning Musicians. Over at Broadway Macau, meanwhile, the Broadway Theatre will showcase a diverse array of captivating performances and music events to ensure a spectacular entertainment experience.

On the first floor of Galaxy Promenade, GalaxyArt presents “Boom and Bloom Exhibition”, a dynamic and engaging art exhibition that offers an exciting fusion of innovation and fun. This exhibition sees the debut collaboration between Mainland artist Ray Chan and Macau-born artist Sanchia Lau with their original IPs “Shake Money Tree” and “Wishing Doll”. Over at Galaxy Cinema, audiences can enjoy Lunar New Year blockbuster films while their little ones experience delightful New Year surprises with the resort’s much-loved mascot, Wavey the Peacock. Hotel guests with young ones can also visit the Edutainment Center for free craft workshops themed around the Lunar New Year.

Culinary Delights for Festive Gatherings

“Poon Choi” is a beloved culinary heritage that reflects the nostalgic charm of Hong Kong’s Yuen Long walled villages. Galaxy Macau celebrates the traditional cuisine with a modern twist this year, infusing the classic dish with the rich, spicy flavours of Sichuan cuisine. Specialty items like Black Cane Sugar New Year Pudding and Chinese Turnip Cake are crafted from premium ingredients to highlight traditional tastes. Various restaurants at the resort will also roll out festive menus, from sumptuous banquet sets to à la carte delights and dim sum, catering to every reunion gathering. Diners using Visa cards at designated restaurants can enjoy an instant discount of MOP 150 when spending MOP 800, as well as dining vouchers worth up to MOP 600. Many prestigious restaurants at StarWorld Hotel also present a myriad of delectable Lunar New Year dishes, including the two-Michelin-starred Feng Wei Ju, ensuring a great start to the year fueled by acclaimed culinary artistry.

Restaurants at StarWorld Hotel, Galaxy Macau and Broadway Macau present a myriad of delectable Lunar New Year dishes for added festivity.
Restaurants at StarWorld Hotel, Galaxy Macau and Broadway Macau present a myriad of delectable Lunar New Year dishes for added festivity.

Explore Macau’s Festive Charm

The “Love Between Fairy and Devil” VR Experience invites guests celebrate a “National Style Chinese New Year” this Spring Festival. Choose from over 200 exquisite Hanfu outfits, complete with professional makeup and hairstyling. Explore Galaxy Macau and other iconic Macau attractions, where tradition meets modernity, as expert photographers capture every beautiful moment for you.

Outside the resort, guests can hop on the open-top sightseeing bus for a short trip and enjoy the glittering festive lights of Cotai. For those who love city walks, 23 locations across Cotai and other areas of Macau offer stunning photo opportunities with the “Light Up Macao: Symphony of Time and Space” installations. Guests can also visit the newly renovated Lai Chi Vun Shipyards, where eye-catching Lunar New Year decorations await. The Spring Market in the Lai Chi Vun Shipyards will open on weekends from January 18 through February 2, as well as on January 31 (the third day of the Lunar New Year). Featuring 18 stalls that offer unique local festive souvenirs, the market is complemented by live music and festive-themed workshops in the afternoon.

Galaxy Entertainment Group Revitalization Project Lai Chi Vun Shipyards Spring Market arrangements.
Galaxy Entertainment Group Revitalization Project Lai Chi Vun Shipyards Spring Market arrangements.

From January 31 (the third day of the Lunar New Year) to February 2, the Lai Chi Vun Shipyards will host even more exciting activities, including the God of Wealth Parade and the handing out of fortune gift bags. Visitors can also enjoy various traditional events unique to Macau, including the Grand Dragon Parade, the Lunar New Year Float Parade, and fireworks displays from January 29 to February 8.

For more information, visit the official website at www.galaxymacau.com, or follow Galaxy Macau on social media (Facebook, Instagram, WeChat, TikTok and Xiaohongshu) for the latest updates. For inquiries and reservations, please call +853 8883 2221.

Hashtag: #GalaxyMacau

The issuer is solely responsible for the content of this announcement.

About Galaxy Macau Integrated Resort

Galaxy Macau™, The World-class Luxury Integrated Resort delivers the “Most Spectacular Entertainment and Leisure Destination in the World”. Developed at an investment of HK$43 billion, the property covers 1.1 million-square-meter of unique entertainment and leisure attractions that are unlike anything else in Macau. Eight award-winning world-class luxury hotels provide close to 5,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel, Raffles at Galaxy Macau, Andaz Macau. Unique to Galaxy Macau, the 75,000-square-meter Grand Resort Deck features the world’s longest Skytop Adventure Rapids at 575-meters, the largest Skytop Wave Pool with waves up to 1.5-meters high and 150-meters pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz- Carlton Spa, Macau help guests relax and rejuvenate.

As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies.

Embark on a delightful and rewarding journey at Galaxy Promenade, the one-stop shopping destination boasting some of the world’s most iconic luxury brands. Be the first to get the latest limited-edition items; explore fascinating pop-ups by coveted labels and revel in fabulous shopping rewards and privileges. Our VIPs are entitled to a highly-curated experience with dedicated personal shoppers at guests’ service, and be invited to exclusive luxury brand events. A different caliber of privileges and rewards also await. Discover the joys of fashion and stand at the forefront of style and sophistication—Galaxy Promenade has everything guests need to stay ahead of the style game.

Galaxy Cinemas takes immersive movie experiences to the next level with the latest audio-visual technology, ultra-luxurious facilities and bespoke services; CHINA ROUGE, one-of-a-kind deluxe lounge that evokes the glitz and glamor of Shanghai’s golden era with entertainment in luxury and style; and Foot Hub presents the traditional art of reflexology to make you feel more relaxed and revitalized. For Authentic Macau Flavors & Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 Authentic Macau & Asian Flavors at its Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events.

Meeting, incentive and banquet groups are also well looked after with a portfolio of unique venues in Galaxy Macau and a professional service staff. Galaxy International Convention Center (GICC) is the latest addition to the Group’s ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world- class event venue featuring 40,000-square-meter of total flexible MICE, and a 16,000-seat Galaxy Arena – the largest indoor arena in Macau.

For more details, please visit and

Gaw Capital Partners Acquires 45% Stake in Agility Asset Advisers Inc.


TOKYO, JAPAN/HONG KONG SAR – Media OutReach Newswire – 16 January 2025 – Real estate private equity firm Gaw Capital Partners, today announces the acquisition of 45% stake in Agility Asset Advisers Inc. (AAA). This strategic partnership with Agility Asset Advisers Inc. further enhances Gaw Capital’s corporate profile and reputation in the Japan real estate market, amplifies its deal sourcing and asset management capabilities, and opens up new avenues to access lower-cost Japanese capital and evergreen funding sources.

Founded in January 2005, Agility Asset Advisers Inc., as a wholly owned subsidiary of Agility Holdings Inc. (AH), has been an integral member of the PhillipCapital Group (PhillipCapital), a comprehensive financial group based in Singapore, since January 2016. Throughout the past years, AAA has built a strong foundation in domestic real estate management for institutional investors.

Under the collaboration, an affiliate company of Gaw Capital and a related company of PhillipCapital, each hold a 45% stake in Agility Asset Advisers Inc. The remaining 10% is held by Mutual Links Corporation (ML), whose majority shareholder is AAA’s founding president, Mr. Kinji Kaiho. The restructured ownership is a testament to the strategic alignment and shared vision between PhillipCapital and Gaw Capital to foster innovation and accelerate growth.

Mr. Kinji Kaiho will remain as President of AAA, ensuring the continuity and stability in the company’s leadership as we embark on this new chapter of collaboration.

Isabella Lo, Managing Director, Principal – Investments and Head of Japan at Gaw Capital Partners, said, “We are excited about the possibilities this collaboration presents. By partnering with Agility Asset Advisers Inc., we are well-positioned to drive growth by redesigning and repositioning under-utilized real estate assets, unlock new opportunities, such as REIT initiatives, and deliver enhanced value to our investors in Japan and beyond.”

This strategic alliance underscores Gaw Capital’s commitment to deepening its presence in Japan and delivering innovative real estate investment solutions to investors worldwide. Together with Agility Asset Advisers Inc., Gaw Capital is poised to make strategic and significant expansion within the Japan market, solidifying its position as a key player in the real estate industry of the region.
Hashtag: #GawCapitalPartners

The issuer is solely responsible for the content of this announcement.

About Gaw Capital Partners

Gaw Capital Partners is a uniquely positioned private equity fund management company focusing on real estate markets in Asia Pacific and other high barrier-to-entry markets globally. Specializing in adding strategic value to under-utilized real estate through redesign and re-positioning, the firm’s investments span the entire spectrum of real estate sectors, including residential development, commercial offices, retail malls, hospitality, logistics warehouses and IDC projects.

Since its inception in 2005, Gaw Capital has raised seven commingled funds targeting Asia Pacific regions. The firm also manages value-add/opportunistic funds in the US, a Pan-Asia hospitality fund, a European Hospitality Fund, a Growth Equity Fund, and it also provides services for credit investments and separate account direct investments globally.

Gaw Capital has raised equity of US$22.9 billion since 2005 and commanded assets of US$35.8 billion under management as of Q3 2024.

About PhillipCapital Group

Since its inception as a stockbroker in 1975, PhillipCapital has grown into an integrated Asian financial house with a global presence and offers a full range of quality and innovative services to retail and high net worth individuals, family offices, as well as corporate and institutional customers.

PhillipCapital offers a comprehensive suite of financial products and services includes broking in securities, futures, foreign exchange, bonds, precious metals and commodities, unit trusts, contracts for difference, exchange traded funds; fund management, managed accounts, insurance planning, regular savings plan, investment research, equity financing and property consultancy. Institutions can also benefit from our corporate finance and advisory services as well as information technology solutions.

Today, the company headquartered in Singapore, operates in the financial hubs of 15 countries, including offices in Australia, Cambodia, China (and Hong Kong SAR), India, Indonesia, Japan, Malaysia, Singapore, Spain, Thailand, Turkey, UK, UAE, USA and Vietnam, serving over 1 million clients with Assets Under Management of total more than USD 50 billion.

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343, a potentially best-in-class TOPO1i anti-CLDN18.2 ADC, as monotherapy for the treatment of CLDN18.2-positive advanced pancreatic ductal adenocarcinoma (PDAC) patients who have progressed after at least one line of prior systematic treatment.

The BTD for IBI343 was granted based on data from an ongoing Phase 1 study conducted in China, Australia and the U.S. (NCT05458219), which demonstrated favorable safety and tolerability, as well as promising antitumor activity of IBI343 monotherapy in advanced PDAC patients. Data from the study’s dose-expansion cohort were presented orally at the 2024 ESMO Asia Congress:

  • A total of 43 patients with CLDN18.2-positive advanced PDAC (≥60% tumor cells with membranous staining intensity ≥1+ by IHC) received IBI343 6 mg/kg Q3W monotherapy. All participants had previously received at least one line of prior therapy, and 60.5% had received two or more lines of anticancer treatment.
  • The confirmed overall objective response rate (ORR) was 23.3%, and progression-free survival (PFS) events occurred in 26 patients, with a median progression-free survival (mPFS) of 5.3 months (4.1-7.4) as of the data cutoff date. (link)

Previously, in May 2024, the CDE has granted IBI343 its first BTD for monotherapy in the treatment of CLDN18.2-positive advanced gastric/gastro-esophageal junction adenocarcinoma (GC) patients who have progressed after at least two lines of prior systematic treatments. In addition, in June 2024, IBI343 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, unresectable or metastatic PDAC that has relapsed and/or is refractory to one prior line of therapy. The first patient in the U.S. Phase 1 study of IBI343 was successfully dosed in December 2024.

Dr. Hui Zhou, Senior Vice President of Innovent, said, “Pancreatic cancer is an aggressive and difficult-to-diagnose malignancy. At present, treatment for advanced pancreatic cancer relies primarily on systemic chemotherapy, with particularly limited options for second-line treatment. This results in poor patient outcomes and underscores an urgent unmet clinical need. As the world’s first CLDN18.2 ADC to receive BTD in this difficult-to-treat cancer, IBI343 monotherapy has shown encouraging efficacy and tolerable safety in late-line treatment of patients with advanced pancreatic cancer. Subject to PoC data readout, we plan to initiate pivotal MRCT studies to further confirm its efficacy and safety in this indication. Additionally, we will also explore the potential of IBI343 in combination therapy for pancreatic cancer and other solid tumors, including gastric cancer.”

NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of investigational drugs for serious diseases or conditions when preliminary clinical evidence indicates substantial improvement over current therapies. BTD qualifies a drug candidate for accelerated review by the CDE and provides the sponsor with timely advice and communication to expedite the approval process, helping to address the unmet clinical needs of patients more swiftly.

About Pancreatic Ductal Adenocarcinoma

Pancreatic cancer is one of the most aggressive malignances of the digestive system, with a 5-year survival rate of about 10%[i]. Despite rising incidence rates in recent years, early detection remains low, seriously endangering human life and health. Current treatment for advanced pancreatic cancer is primarily based on systemic chemotherapy, with first-line treatment options typically including fluorouracil (5-FU) or gemcitabine-based chemotherapy. However, second-line treatment options are limited, offering a chemotherapy response rate of only 6-16%, a median progression free survival of 2 to 5 months, and a median overall survival of approximately 6 to 9 months[ii]. These statistics highlight the urgent need for new therapeutic approaches.

Claudin, a member of the tight junction molecule family, is a key structural and functional component of epithelial tight junctions. Among them, CLDN18.2 is normally confined to the gastric mucosa. The development of malignancy leads to disruption of tight junctions and exposure of CLDN18.2 epitopes on the membrane of tumor cells[iii]. CLDN18.2 is present in 50% to 70% of pancreatic cancer cases, making it a highly targeted biomarker for therapeutic development[iv].

About IBI343 (CLDN18.2 ADC)

IBI343 is an antibody-drug conjugate composed of an anti-CLDN18.2 antibody, and a cytotoxic drug exatecan. Binding of IBI343 to CLDN18.2-expressing tumor cells results in CLDN18.2-dependent internalization of IBI343. Degradation of the cleavable linker will release the drug that causes DNA damage, leading to apoptosis of the tumor cells. The freed drug can also diffuse across the plasma membrane to reach and kill the neighboring tumor cells, resulting in a strong “bystander killing effect” of IBI343. As an innovative TOPO1i ADC, IBI343 has demonstrated tolerable safety and encouraging efficacy signals in Phase 1 clinical studies. The therapeutic potential of IBI343 is currently being explored in tumor types such as gastric and pancreatic cancers, including a Phase 3 trial (NCT06238843) for GC and a multi-regional Phase 1 trial (NCT05458219) for PDAC ongoing.

IBI343 was granted breakthrough therapy designation (BTD) by China’s National Medical Products Administration (NMPA) for two indications,  as monotherapy in patients with CLDN18.2–positive GC who progressed after two prior lines of systemic treatment, and in patients with CLDN18.2-positive PDAC who have progressed after at least one line of prior systematic treatment. IBI343 also received Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of advanced unresectable or metastatic PDAC that has relapsed and/or is refractory to one prior line of therapy.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:
1Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2Ramucirumab (Cyramza), Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

[i] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33. doi: 10.3322/caac.21708.

[ii] Ettrich T J, Seufferlein T. Systemic therapy for metastatic pancreatic cancer[J]. Current treatment options in oncology, 2021, 22(11): 106.

[iii] Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634.

[iv] Wu YY, Fan L, Liao XH, et al. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol. 2022 Jul 15;14(7):1252-1264.

Hurom Secures Victory in Korea Trade Commission Case Against NUC (Kuvings)

NUC Found Guilty of Patent Infringement, Ordered to Cease Activities, Pay Fines

SEOUL, South Korea, Jan. 16, 2025 /PRNewswire/ — Hurom, the pioneer of low-speed masticating juicers and a global market leader, has successfully proven patent infringement by NUC, manufacturer of the Kuvings juicer line, in an investigation by the Korea Trade Commission (KTC). The investigation (Remedy 4-1-2023-8) concluded that NUC engaged in unfair trade practices.

On December 19, 2024, the KTC ruled that NUC had infringed Hurom’s patent rights, constituting unfair trade practices. The KTC issued a corrective order, imposed fines, and formally notified NUC of its decision. 

The investigation began in December 2023 when Hurom filed a complaint with the KTC. After initiating the inquiry in January 2024, the KTC announced its findings on December 19, acknowledging NUC’s unfair practices, with final notification issued on December 31.

Under the KTC ruling, NUC has been ordered to cease the export and domestic manufacturing for export of its AUTO10 juicer model, dispose of all existing inventory, publicly disclose its patent infringement along with the corrective order, and pay a fine of ₩152.5 million ($105,000 USD).

This ruling builds on a similar decision made in July 2023 through Amazon’s Amazon Patent Evaluation Express (APEX) process (APEX ID: 15060613361), which found NUC guilty of patent infringement. That decision led to the suspension of sales for five key NUC models in the United States: REVO830W, EVO820GM, C7000S, C7000W, and C7000P. The KTC’s acknowledgment of unfair trade practices further strengthens Hurom’s case.  

Founded in 1974, Hurom has dedicated over 50 years to advancing juicing technology, culminating in the creation of the world’s first vertical masticating juicer in 2005. As a global leader in health innovation, Hurom has set the standard for vertical juicing systems.

Hurom is also pursuing legal action in the Unified Patent Court (UPC) in Europe against manufacturers and distributors infringing on its patents. The company remains steadfast in protecting its proprietary technologies through robust legal efforts.

*UPC cases in Germany: PR_ACT_17336/2024, PR_ACT_17365/2024

*UPC case in France: PR_ACT_17434/2024

Ridgewood Infrastructure Announced $1.2 Billion Final Close for Fund II, Significantly Surpassing Its Target

NEW YORK, Jan. 16, 2025 /PRNewswire/ — Ridgewood Infrastructure (“Ridgewood”), a leading investor in essential infrastructure in the U.S. lower middle market, today announced the final close of its second fund, Ridgewood Water & Strategic Infrastructure Fund II LP (“Fund II”), with $1.2 billion in capital commitments, significantly surpassing its $1 billion target.

Fund II attracted a diverse mix of leading institutional investors, including returning and new public and corporate pensions, insurance companies, endowment funds, and asset managers from North America, Europe, Asia, and the Middle East.

A continuation of Ridgewood’s established strategy, Fund II is focused on investments in essential infrastructure businesses and assets that provide critical services in sectors including water, energy, transportation, and utilities. Ridgewood’s operationally oriented, value creation approach emphasizes scaling, professionalizing, and enhancing the strategic positioning of its investments.

“We are grateful for the continued significant support from our existing partners and are excited to welcome several new LPs from across the globe,” said Ross Posner, Managing Partner of Ridgewood Infrastructure. “This is a meaningful milestone for our firm, and we are deeply appreciative of the trust our partners continue to place in our team and strategy.”

Michael Albrecht, Managing Partner, added: “We look forward to continuing to deliver value for our investors and the many communities in which our portfolio companies operate.”

Fund II has already made several notable investments, including the Prospect Lake Clean Water Center, the third-largest water public-private partnership in U.S. history, which will provide approximately 80% of Fort Lauderdale’s fresh water under a 30-year concession agreement.

Ridgewood has also had notable recent exits from its inaugural fund (“Fund I”). Last October, Fund I sold its controlling interest in the Vista Ridge Water Pipeline, America’s largest water public-private partnership, which supplies approximately 20% of San Antonio’s fresh water under a 30-year concession agreement. Earlier this month, Fund I also sold its controlling interest in SiEnergy, one of the fastest growing regulated utilities in America.

“Our achievements reflect the exceptional capabilities of our team and the strength of the Ridgewood platform,” said Matthew Swanson, Founding Partner of Ridgewood Infrastructure. “We look forward to building upon this strong foundation of success in the years to come.”

Eaton Partners, a Stifel company, acted as the placement agent, and Vinson & Elkins LLP served as legal counsel for the fund.

About Ridgewood Infrastructure
Ridgewood Infrastructure is a leading infrastructure investor in the U.S. lower middle market with sectors of focus including water, energy, transportation, and utilities. For more information, visit www.ridgewoodinfrastructure.com.

Contact Information: Ridgewood Infrastructure
527 Madison Avenue, 18th Floor
New York, NY 10022
Phone: (212) 867-0050
Email: Inquiries@RidgewoodInfrastructure.com

Logo – https://laotiantimes.com/wp-content/uploads/2025/01/ridgewood_logo.jpg